Medtronic Valuation Multiples

Medtronic is valued at $130B as of November 2026, a 4.0x revenue multiple. In the last 12 months, Medtronic revenue was $38B and Medtronic EBITDA was $11B.

Medtronic Overview

About Medtronic

Medtronic is a global medical-technology company founded in 1949 and legally headquartered in Ireland, with major operating leadership in Minnesota. It develops and manufactures therapeutic and diagnostic devices for cardiovascular disease, diabetes, neurological conditions, spinal disorders, surgical care and other chronic health problems. Products include pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, ablation systems, patient-monitoring equipment and surgical tools. Hospitals, clinicians and healthcare systems buy the company's devices, disposable supplies, software and related services. Medtronic earns most of its revenue from product sales and serves customers across the Americas, Europe, Asia and other international markets. The company is publicly listed and maintains a large global research, manufacturing and commercial organization. Its cardiovascular strategy includes minority investments, partnerships and acquisitions of specialist medical-device developers. Medtronic invested in CathWorks, co-promoted its FFRangio system and completed the acquisition of the remaining shares for $585 million in April 2026.


Founded

1949

HQ

United States

Employees

95.0K

Financials (LTM)

Revenue: $38B
EBITDA: $11B

EV

$150B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Medtronic Financials

Medtronic reported last 12-month revenue of $38B and EBITDA of $11B.

In the same LTM period, Medtronic generated $25B in gross profit, $11B in EBITDA, and $7.4B in net income.

Revenue (LTM)


Medtronic P&L

In the most recent fiscal year, Medtronic reported revenue of $36B and EBITDA of $9.9B.

Medtronic is profitable as of last fiscal year, with gross margin of 65%, EBITDA margin of 27%, and net margin of 13%.

See analyst estimates for Medtronic
LTMLast FY202320242025202620272028
Revenue$38B$36B$32B$33B$36B
Gross Profit$25B$24B$21B$22B$24B
Gross Margin65%65%65%65%65%
EBITDA$11B$9.9B$8.4B$8.9B$10B
EBITDA Margin28%27%26%27%28%
EBIT Margin25%19%18%19%24%
Net Profit$7.4B$4.8B$3.7B$4.3B$7.1B
Net Margin20%13%12%13%20%
Net Debt-$26B---

Financial data powered by Morningstar, Inc.

Medtronic Stock Performance

Medtronic has current market cap of $130B, and enterprise value of $150B.

Market Cap Evolution


Medtronic's stock price is $101.61.

Medtronic share price increased by 5.3% in the last 30 days, and decreased by 3.5% in the last year.

Medtronic has an EPS (earnings per share) of $3.75.

See more trading valuation data for Medtronic
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$150B$130B0.0%5.3%12.1%-3.5%$3.75

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Medtronic Valuation Multiples

Medtronic trades at 4.0x EV/Revenue multiple, and 14.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Medtronic

EV / Revenue (LTM)


Medtronic Financial Valuation Multiples

As of November 12, 2026, Medtronic has market cap of $130B and EV of $150B.

Medtronic has a P/E ratio of 17.5x.

LTMLast FY202320242025202620272028
EV/Revenue4.0x4.1x4.7x4.5x4.1x
EV/EBITDA14.1x15.2x17.9x16.9x14.9x
EV/EBIT16.1x22.0x26.7x24.2x16.9x
EV/Gross Profit6.1x6.3x7.2x6.9x6.3x
P/E17.5x27.1x35.1x30.0x18.3x
EV/FCF25.8x27.6x30.0x28.9x27.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Medtronic Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Medtronic Margins & Growth Rates

Medtronic grew revenue by 7% and EBITDA by 12% in the last fiscal year.

In the most recent fiscal year, Medtronic reported gross margin of 65%, EBITDA margin of 27%, and net margin of 13%.

See estimated margins and future growth rates for Medtronic

Medtronic Margins

Last FY202420252026202720282029
Gross Margin65%65%65%65%
EBITDA Margin27%27%28%28%
EBIT Margin19%19%24%23%
Net Margin13%13%20%18%
FCF Margin15%16%15%15%

Medtronic Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%4%10%5%
Gross Profit Growth7%3%10%4%
EBITDA Growth12%6%13%6%
EBIT Growth42%10%43%(1%)
Net Profit Growth60%17%64%(6%)
FCF Growth13%4%5%8%

Data powered by FactSet, Inc. and Morningstar, Inc.

Medtronic Operational KPIs

Medtronic's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Medtronic's Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medtronic's Rule of X is 40% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Medtronic
LTMLast FY202320242025202620272028
Rule of 4033%33%---
Bessemer Rule of X41%40%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
R&D Expenses to Revenue8%8%9%8%8%
Opex to Revenue-46%48%47%45%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Medtronic Competitors

Medtronic competitors include Stryker, Intuitive Surgical, Danaher, Abbott, Boston Scientific, Edwards Lifesciences, IDEXX Laboratories, Siemens Healthineers, Agilent and Waters.

Most Medtronic public comparables operate across Medical Devices, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Stryker$25B$6.3B5.3x5.0x21.1x17.5x
Intuitive Surgical$10B$3.6B15.1x13.0x42.7x28.2x
Danaher$25B$6.9B7.6x7.2x27.0x22.4x
Abbott$44B$12B4.9x4.4x18.4x16.7x
Boston Scientific$20B$5.1B3.8x3.7x15.2x11.9x
Edwards Lifesciences$6.1B$1.3B9.4x8.5x44.5x27.0x
IDEXX Laboratories$4.3B$1.5B13.0x12.0x37.3x33.5x
Siemens Healthineers$26B$4.9B1.9x1.9x10.5x10.0x

This data is available for Pro users. Sign up to see all Medtronic competitors and their valuation data.

Start Free Trial

Acquisitions by Medtronic

Medtronic has acquired 40 companies to date.

Last acquisition by Medtronic was on May 20th 2026. Medtronic acquired SPR Therapeutics for $650M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Medtronic

SPR Therapeutics
CathWorks
Scientia Vascular
Fortimedix
Description
SPR Therapeutics is a Cleveland-headquartered medical device company commercializing the SPRINT peripheral nerve stimulation system for chronic pain relief. FDA-cleared in 2019, the implantable device delivers 60-day therapy to nerves like the tibial for post-amputation pain. The firm conducts trials for low back pain and partners with VA hospitals across 20 states for over 1,000 patient treatments annually.
CathWorks is an Israeli medical-device and computational-cardiology company founded in 2013. Its FFRangio system analyzes routine coronary angiograms to produce a three-dimensional model and physiological assessment of blood flow throughout the coronary tree. Cardiologists use the technology during catheterization procedures to evaluate coronary artery disease and decide whether a patient is likely to benefit from revascularization. The system combines artificial intelligence and computational science and avoids the pressure wires and drug-induced hyperemia required by traditional fractional-flow-reserve measurement. CathWorks sells systems and related products to hospitals and catheterization laboratories. Medtronic invested up to $75 million in the company in 2022 and entered a global co-promotion arrangement covering the United States, Europe and Japan. Medtronic exercised its purchase option in 2026 and completed the $585 million acquisition on April 20, 2026, bringing CathWorks into its cardiovascular portfolio.
Scientia Vascular is a medical device company designing neurovascular access tools for interventional procedures. Products include guide catheters, microcatheters, and wires engineered for tortuous anatomy in stroke treatment and aneurysm coiling. Utah-based since 2013, the firm prioritizes precision shapes and trackability to improve outcomes in minimally invasive endovascular therapies. Devices reach specialists in North America and Europe through distribution networks.
Fortimedix is an Enschede-based manufacturer of precision endovascular stents and delivery systems for cardiovascular interventions. Established over 15 years ago, the company provides in-house design, prototyping, and production capabilities using advanced nitinol processing and laser micromachining technologies. Acquired by OrbusNeich in 2021, Fortimedix supports medical device companies worldwide with custom stent solutions for peripheral and coronary artery treatments.
HQ CountryUnited StatesIsraelUnited StatesNetherlands
HQ City
Cleveland, OH
Tel Aviv
Salt Lake City, UT
Heerlen
Deal Date20 May 202620 Apr 20269 Mar 202621 Nov 2024
Valuation$650M$585M$550Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Medtronic acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Medtronic

Medtronic has invested in 32 companies to date.

Latest investment by Medtronic was on September 1st 2026. Medtronic invested in Pi-Cardia in their $80M Strategic investment round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Medtronic

Pi-Cardia
Cornerstone Robotics
CoreMap
RapidPulse
Description
Pi-Cardia is an Israeli medical technology company based in Rehovot that develops non-implant, catheter-based devices for treating heart valve calcification, particularly aortic stenosis, without requiring valve replacement. Its ShortCut leaflet modification device, cleared by the FDA, is used to modify diseased valve leaflets ahead of complex transcatheter aortic valve replacement (TAVR) procedures, including cases at risk of coronary obstruction during valve-in-valve TAVR. The company's earlier Leaflex technology used mechanical scoring to fracture calcified valve leaflets and restore valve mobility as a potential alternative to TAVR for heavily calcified or bicuspid valves.
Cornerstone Robotics is a Hong Kong-based developer of surgical robots. Its Sentire system is a robot-assisted endoscopic surgery platform approved by China's NMPA in 2024. It has a manufacturing facility in China.
CoreMap is a medical device company developing diagnostic tools for electrophysiologists treating cardiac arrhythmias. Its platform combines high-density mapping catheters with software for real-time visualization of electrical signals in the heart. Minneapolis-headquartered, CoreMap focuses on improving ablation procedures for atrial fibrillation through precise 3D reconstructions and AI-assisted analysis.
RapidPulse is a U.S.-based medical device company developing the Cyclic Aspiration System for ischemic stroke treatment. The platform features a portable pump delivering pulsatile suction to remove clots from cerebral arteries up to 20 mm in size. Clinical trials at centers like Mount Sinai demonstrate 90 percent first-pass recanalization rates. Originating from Syntheon, it targets the $2 billion neurothrombectomy market with FDA Breakthrough Device Designation received in 2021.
HQ CountryIsraelHong KongUnited StatesUnited States
HQ City
Rehovot
Hong Kong
-
Miami, FL
Deal Date1 Sep 20261 Sep 202628 Jul 202615 Jul 2026
RoundStrategic investmentStrategic investmentSeries CSeries B
Raised$80M$700M$37M$48M
InvestorsMedtronicMedtronicMedtronicMedtronic; Florida Opportunity Fund; S3 Ventures; SBI Investment; TechWald Holding S.p.A.; Epidarex Capital; Sante Ventures; Hatteras Venture Partners; Syntheon
Valuation$210Mundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Medtronic investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Medtronic

When was Medtronic founded?Medtronic was founded in 1949.
Where is Medtronic headquartered?Medtronic is headquartered in United States.
How many employees does Medtronic have?As of today, Medtronic has over 95K employees.
Who is the CEO of Medtronic?Medtronic's CEO is Que Thanh Dallara.
Is Medtronic publicly listed?Yes, Medtronic is a public company listed on NYSE.
What is the stock symbol of Medtronic?Medtronic trades under MDT ticker.
When did Medtronic go public?Medtronic went public in 1972.
Who are competitors of Medtronic?Medtronic main competitors include Stryker, Intuitive Surgical, Danaher, Abbott, Boston Scientific, Edwards Lifesciences, IDEXX Laboratories, Siemens Healthineers, Agilent, Waters.
What is the current market cap of Medtronic?Medtronic's current market cap is $130B.
What is the current revenue of Medtronic?Medtronic's last 12 months revenue is $38B.
What is the current revenue growth of Medtronic?Medtronic revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Medtronic?Current revenue multiple of Medtronic is 4.0x.
What is the current EBITDA of Medtronic?Medtronic's last 12 months EBITDA is $11B.
What is Medtronic's EBITDA margin?Medtronic's last 12 months EBITDA margin is 28%.
What is the current EV/EBITDA multiple of Medtronic?Current EBITDA multiple of Medtronic is 14.1x.
What is the current FCF of Medtronic?Medtronic's last 12 months FCF is $5.8B.
What is Medtronic's FCF margin?Medtronic's last 12 months FCF margin is 15%.
What is the current EV/FCF multiple of Medtronic?Current FCF multiple of Medtronic is 25.8x.
How many companies Medtronic has acquired to date?As of November 2026, Medtronic has acquired 40 companies.
What was the largest acquisition by Medtronic?$43B acquisition of Covidien on 15th June 2014 was the largest M&A Medtronic has done to date.
What companies Medtronic acquired?Medtronic acquired Covidien, Mazor Robotics, Intersect ENT, HeartWare International, Affera, SPR Therapeutics, CathWorks, Scientia Vascular, NGC Medical SpA, Twelve, and 30 other companies.
In how many companies Medtronic has invested to date?As of November 2026, Medtronic has invested in 32 companies.

See public comps similar to Medtronic

Lists including Medtronic

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial